PETROS PHARMACEUTICALS INC (PTPI) Stock Price, Quote, News and Overview
NASDAQ:PTPI - Nasdaq - US71678J2096 - Common Stock - Currency: USD
PTPI Quote, Performance and Key Statistics
PETROS PHARMACEUTICALS INC
NASDAQ:PTPI (2/18/2025, 4:26:40 PM)
After market: 0.1405 +0 (+3.08%)0.1363
-0.15 (-53%)
The current stock price of PTPI is 0.1363 USD. In the past month the price decreased by -2.33%. In the past year, price decreased by -80.47%.
PTPI Latest News, Press Relases and Analysis
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.
Unusual volume stocks in Tuesday's session
Discover the stocks with unexpected trading volume in today's session on the US markets.
Which stocks are moving on Tuesday?
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Tuesday's session: gap up and gap down stocks
Let's have a look at the gap up and gap down stocks in today's session.
PTPI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 65.94 | 813.76B | ||
| JNJ | JOHNSON & JOHNSON | 15.51 | 373.16B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 25.65 | 365.47B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.72 | 231.97B | ||
| MRK | MERCK & CO. INC. | 10.9 | 210.69B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.43 | 210.56B | ||
| PFE | PFIZER INC | 8.22 | 144.85B | ||
| SNY | SANOFI-ADR | 13.45 | 135.26B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 47.75 | 110.39B | ||
| GSK | GSK PLC-SPON ADR | 7.81 | 74.71B | ||
| ZTS | ZOETIS INC | 26.43 | 70.60B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.33 | 44.07B |
Related stock screener links
About PTPI
Company Profile
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. The company is headquartered in New York City, New York and currently employs 21 full-time employees. The company went IPO on 2020-12-02. The firm is pursuing access to its flagship prescription erectile dysfunction (ED) therapy, Stendra, via potential OTC designation. Stendra is a Phosphodiesterase - 5 (PDE - 5) inhibitor prescription medication for the treatment of ED and is the only patent protected PDE-5 inhibitor on the market. Stendra offers the ED therapeutic landscape a valuable addition as an oral ED therapy that may be taken once daily as early as approximately 15 minutes prior to sexual engagement, with or without food, when using the 100mg or 200mg dosing, subject to certain contraindications and limitations common among PDE-5 inhibitors. The company also markets its own line of medical devices intended for ED treatment through its subsidiaries, Timm Medical and PTV, including the VED systems marketed as Osbon ErecAid and PosTVac.
Company Info
PETROS PHARMACEUTICALS INC
1185 Avenue Of The Americas, 3Rd Floor, Suite 570
New York City NEW YORK 10036 US
CEO: John D. Shulman
Employees: 21
Company Website: https://www.petrospharma.com/
Investor Relations: http://irdirect.net/PTPI/sec_filings
Phone: 19732420005
PTPI FAQ
What is the stock price of PTPI?
The current stock price of PTPI is 0.1363 USD.
What is the symbol for PETROS PHARMACEUTICALS INC stock?
The exchange symbol of PETROS PHARMACEUTICALS INC is PTPI and it is listed on the Nasdaq exchange.
On which exchange is PTPI stock listed?
PTPI stock is listed on the Nasdaq exchange.
Is PTPI a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for PTPI, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of PTPI.
Does PTPI stock pay dividends?
PTPI does not pay a dividend.
What is the Price/Earnings (PE) ratio of PTPI?
PTPI does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.88).
What is the Short Interest ratio of PTPI stock?
The outstanding short interest for PTPI is 7.83% of its float.
PTPI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PTPI. When comparing the yearly performance of all stocks, PTPI is a bad performer in the overall market: 92.56% of all stocks are doing better.
PTPI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PTPI. PTPI may be in some trouble as it scores bad on both profitability and health.
PTPI Financial Highlights
Over the last trailing twelve months PTPI reported a non-GAAP Earnings per Share(EPS) of -4.88. The EPS decreased by -48.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -144.12% | ||
| ROE | -956.75% | ||
| Debt/Equity | 1.58 |
PTPI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to PTPI. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 58.64% and a revenue growth -29.45% for PTPI